Evidence map›Paper›PMID 40858115›Full record

ArticleCell2025

Transient gene melting governs the timing of oligodendrocyte maturation.

Kevin C Allan, Jesse J Zhan, Andrew R Morton, Erin F Cohn, Marissa A Scavuzzo, Anushka Nikhil, Matthew S Elitt, Benjamin L L Clayton, Lucille R Hu, H Elizabeth Shick and 11 more

Abstract read
In one paragraph

Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Kevin C AllanDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Jesse J ZhanDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Andrew R MortonDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Erin F CohnDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Marissa A ScavuzzoDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Anushka NikhilDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Matthew S ElittDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Benjamin L L ClaytonDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Lucille R HuDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
H Elizabeth ShickDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Jost K VrabicDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Hannah E OlsenDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Daniel C FactorDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Jonathan E HenningerWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Gemma BachmannIonis Pharmaceuticals, Carlsbad, CA 92010, USA.
Berit E PowersIonis Pharmaceuticals, Carlsbad, CA 92010, USA.
Richard A YoungWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Charles Y LinDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
Peter C ScacheriDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Tyler E MillerInstitute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Department of Pathology and Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Paul J TesarDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Institute for Glial Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Electronic address: paul.tesar@case.edu.

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Modulating Glial Fate and Function in Development and DiseaseR35NS116842 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI Paul Joseph Tesar · 2020 to 2026
$5.3M
Transcriptional regulation in mammalian cellsR35GM144283 · NIGMS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI RICHARD YOUNG · 2022 to 2026
$4.0M
Training in Neurodegenerative DiseasesT32NS077888 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI Xiongwei Zhu · 2013 to 2026
$1.8M
Targeting myeloid cells to increase efficacy of immunotherapy against brain tumors.K08CA276819 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tyler Eugene Miller · 2023 to 2026
$846k
Targeting epigenetic regulation to disrupt glioma stem cell maintenance.F30CA183510 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI MILLER, TYLER EUGENE · 2014 to 2017
$189k
Mechanism of hypoxia mediated failure of oligodendrocyte generationF30HD096784 · NICHD · CASE WESTERN RESERVE UNIVERSITY · PI ALLAN, KEVIN CAMERON · 2019 to 2022
$163k
Pathological Mechanotransduction by Oligodendrocytes After Traumatic Brain InjuryF31NS124282 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI COHN, ERIN FRANCES · 2021 to 2024
$139k
Cis-regulation of EGFR in glioblastomaF30CA236313 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MORTON, ANDREW ROBERT · 2019 to 2020
$96k
NCI NIH HHS F30 CA183510NCI NIH HHS F30 CA236313NCI NIH HHS K08 CA276819NCI NIH HHS P30 CA043703NICHD NIH HHS F30 HD096784NIGMS NIH HHS R35 GM144283NIGMS NIH HHS T32 GM007250NINDS NIH HHS F31 NS124282NINDS NIH HHS R35 NS116842NINDS NIH HHS T32 NS077888
6 · The paper itself

Abstract

Cellular maturation is a crucial step for tissue formation and function, distinct from the initial steps of differentiation and cell fate specification. In the central nervous system, failure of oligodendrocyte maturation is linked to diseases such as multiple sclerosis. Here, we report a transcriptional mechanism that governs the timing of oligodendrocyte maturation. After progenitor cells differentiate into immature oligodendrocytes, the transcription factor SOX6 redistributes from super-enhancers to cluster across specific gene bodies. These sites exhibit extensive chromatin decondensation and transcription, which abruptly turn off upon maturation. Suppression of SOX6 deactivates these immaturity loci, accelerating the transition to mature, myelinating oligodendrocytes. Notably, cells harboring this immature SOX6 gene signature are enriched in multiple sclerosis patient brains and antisense oligonucleotide-mediated Sox6 knockdown drives oligodendrocyte maturation in mice. Our findings establish SOX6 as a key regulator of oligodendrocyte maturation and highlight its potential as a therapeutic target to promote myelination in disease.

Indexed as

OligodendrogliaSOXD Transcription FactorsAnimalsBrainCell DifferentiationChromatinHumansMiceMultiple SclerosisMyelin SheathChromatinSOX6 protein, humanSOXD Transcription Factorsdevelopmentdifferentiationepigeneticmaturationmultiple sclerosismyelinoligodendrocyteSox6

Identifiers

PMID40858115
PMCPMC12926747

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.